3,7-dimethylnon-6-en-1-yn-3-ol

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: well documented guideline study

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1997

Report date:

1997

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

fixed dose procedure

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

3,7-dimethylnon-6-en-1-yn-3-ol

EC Number:

246-061-9

EC Name:

3,7-dimethylnon-6-en-1-yn-3-ol

Cas Number:

24173-47-5

Molecular formula:

C11H18O

IUPAC Name:

3,7-dimethylnon-6-en-1-yn-3-ol

Test animals

Species:

rat

Sex:

male/female

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

unchanged (no vehicle)

Doses:

2000, 500 mg/kg bw

No. of animals per sex per dose:

5 per sex per dose

Control animals:

no

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Any other information on results incl. tables

-

Applicant's summary and conclusion

Interpretation of results:

sligthly toxic

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

according to EU legislation no classification required

Executive summary:

The purpose of this study was to assess the acute oral toxicity of the test article, Ethyldehydrolinalool, in the rat using the fixed dose method. Since the results of the range finding study indicated that a dose level of 2000mg/kg produced

no mortality, in the main study the test article was administered at 2000mg/kg as a single oral dose to a group of 5 male and 5 female rats which had been fasted overnight. The animals were examined frequently on the day of dosing and daily thereafter for a further 14 days at the end of which, the survivors were killed and subjected to necropsy.

As one animal in this first group died, test article at a dose level of 500mg/kg was administered to a second group of 5 males and 5 females. These animals were examined daily for 15 days and were then killed and subjected to necropsy.

Treatment with the test article at a dose level of 2000mg/kg produced incoordination, hypoactivity and piloerection in all animals and a hunched posture in most animals from the day of dosing. In one male clinical signs were markedly more severe and as a consequence, it was killed 4 hours after dosing. All the females and 3 of the surviving males appeared to have

recovered by day 3 and the fourth male survivor had a healthy appearance from day 4. Treatment with the test article at a dose level of 500mg/kg produced no mortalities or clinical signs of toxicity and all animals maintained a healthy appearance throughout the 15 day observation period.

There was no adverse effect on bodyweight gain in any animal of either sex dosed with test article at 500 or 2000mg/kg.

There were no significant abnormalities detected at necropsy in any animal treated with test article at 500 or 2000mg/kg.